Business Value Outcomes

Investment and application of AI in the pharmaceutical industry is rapidly gaining momentum. The AI: Business Value Outcomes track will bring together CEOs, CDOs, CIOs, CTOs, and Global AI, IT, and informatics experts from leading pharmaceutical and technology companies to give strategic talks from a business perspective—allowing you to assess the value of investing in and implementing AI.

Preliminary Agenda

AI in Pharma: Market Size, Investment Opportunities, and Impact of AI

Alan Louie, PhD, Research Director, Life Sciences, IDC

Organizing AI Capabilities to Deliver Business Value throughout the Drug Development Pipeline

Milind Kamkolkar, Chief Data Officer, Cellarity; Former Chief Data Officer, Sanofi

Establishing Leadership Roles: The Search for Senior Leaders in a Young Industry

Ed Bowen, PhD, Vice President, AI & Machine Learning, GSK

FIRESIDE CHAT: Examining Industry Collaborations and Capital Formation

Annastasiah Mudiwa Mhaka, PhD, Co-Founder & President, Alliance for Artificial Intelligence in Healthcare (AAIH)

AI & Strategy Development: Collaboration, Externalisation, Data Sharing, and Integration

Nick Lynch, PhD, Founder and CTO, Curlew Research; External Liaison and Advisor, Pistoia Alliance

Bridging Business and Technical Functions: How to Translate AI Between the Two

Brandon Allgood, PhD, VP, Head of Technology and Innovation, Integral Health; Co-Founder and Vice Chair, Alliance for Artificial Intelligence in Healthcare (AAIH)

Enterprise-Wide Data Science Innovation and Enabled Business Strategies

Srikanth Ramakrishnan, Director, Intelligent Automation/Data Science, Johnson & Johnson Technology

Real-World Data and AI Hype: Stimulating and Supporting Each Other

Dorothee B. Bartels, PhD, Digital Real-World Data Expert; Former Chief Digital Science Officer, BI X (Boehringer Ingelheim’s Digital Lab)

How to Leverage Data Science in the Pharmaceutical Industry

Abel Archundia, Global Head of IT & Digital Transformation, Bayer Pharmaceuticals


Platinum Sponsors